Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Two-Part (Open-Label Followed by Double-Blind) Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of KH607 in the Treatment of Adult Participants With Moderate or Severe Major Depressive Disorder

NCT07101120 is registered in ClinicalTrials.gov with Chengdu Kanghong Pharmaceutical Group Co., Ltd. as lead sponsor.

NCT NCT07101120
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07101120 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Two-Part (Open-Label Followed by Double-Blind) Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of KH607 in the Treatment of Adult Participants With Moderate or Severe Major Depressive Disorder
Lead sponsor
Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
March 19, 2025
Completion date
February 9, 2026
Enrollment
126 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder (mdd)